Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial

@article{Tsuji2011ComparativeTO,
  title={Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial},
  author={Daiki Tsuji and Yong-Il Kim and Keisei Taku and Shigeru Nakagaki and Yoshito Ikematsu and Hiromi Tsubota and Masato Maeda and Naoya Hashimoto and Masayuki Kimura and Takashi Daimon},
  journal={Supportive Care in Cancer},
  year={2011},
  volume={20},
  pages={1057-1064}
}
A single 3 mg or 40 μg/kg intravenous dose of granisetron combined with dexamethasone is routinely used in several countries, although the antiemetic guidelines have recommended granisetron at the dose of 1 mg or 10 μg/kg. A randomized, multicenter trial was conducted to determine the optimal intravenous granisetron dose, 1 or 3 mg, in cancer patients receiving emetogenic chemotherapy. We enrolled 365 patients and randomly assigned them to receive intravenous granisetron 3 mg (3-mg group) or 1… CONTINUE READING
3 Citations
28 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 28 references

a non-inferiority trial

  • M Yonemura, N Katsumata, +11 authors patients vomiting in cancer
  • Jpn J Clin Oncol 39(7):443–448 1064 Support…
  • 2012
Highly Influential
9 Excerpts

Similar Papers

Loading similar papers…